Coronary CTA-Derived Fractional Flow Reserve Can ID Three-Year Outcomes in Angina
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
TUESDAY, Sept. 12, 2023 -- For patients with stable angina pectoris, a coronary computed tomography angiography (CTA)-derived fractional flow reserve (FFR) can identify the three-year risk for all-cause death or nonfatal spontaneous myocardial infarction, according to a study published online Sept. 12 in Radiology.
Kristian T. Madsen, M.D., from the University Hospital of Southern Denmark in Esbjerg, and colleagues examined the prognostic value of coronary CTA-derived FFR test results on three-year clinical outcomes in patients with coronary stenosis. Participants included 900 patients with new-onset stable angina pectoris who underwent coronary CTA-derived FFR; a lesion-specific value of 2 cm with distal-to-stenosis value at or below 0.80 was considered an abnormal test result.
Of the participants, 523 had normal results and 377 had abnormal results from coronary CTA-derived FFR. The researchers found that 2.1 and 6.6 percent of patients with normal and abnormal coronary CTA-derived FFR results, respectively, met the primary end point (composite of all-cause death and nonfatal spontaneous myocardial infarction; relative risk, 3.1). Among those with high levels of coronary artery calcium, the primary end point occurred in 2.2 and 9.0 percent of participants with normal and abnormal coronary CTA-derived FFR results, respectively (relative risk, 4.1).
"Our study provides evidence for the prognostic potential of CT-FFR in patients with high coronary artery calcium scores," Madsen said in a statement. "Regardless of the patient's baseline risk and extent of coronary artery disease measured by coronary artery calcium, if CT-FFR results are normal, the prognosis is good."
Several authors disclosed ties to the medical device industry.
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted September 2023
Read this next
AI-Assisted Contours Superior to Cognitively Defined Prostate Cancer Contours
WEDNESDAY, July 3, 2024 -- Artificial intelligence (AI)-assisted definition of prostate cancer contours reduces underestimation of the extent of prostate cancer, according to a...
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
Patient–Primary Care Provider Language Concordance Tied to Better Outcomes
TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.